相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
C. Reasner et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
D. Williams-Herman et al.
DIABETES OBESITY & METABOLISM (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study
Debora Williams-Herman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
Viswanathan Mohan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
Itamar Raz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes
R. Scott et al.
DIABETES OBESITY & METABOLISM (2008)
Sitagliptin with metformin: Profile of a combination for the treatment of type 2 diabetes
Baptist Gallwitz
DRUGS OF TODAY (2007)
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
Barry J. Goldstein et al.
DIABETES CARE (2007)
Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care
M. N. Cook et al.
DIABETIC MEDICINE (2007)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Epidemic obesity and type 2 diabetes in Asia
Kun-Ho Yoon et al.
LANCET (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
I. Raz et al.
DIABETOLOGIA (2006)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes
Gary A. Herman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Weight Gain in Type 2 Diabetics with Different Treatment Modalities
Hemraj B. Chandalia et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Inhibitors of dipeptidyl peptidase IV:: a novel approach for the prevention and treatment of Type 2 diabetes?
CF Deacon et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2004)
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
JJ Holst et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
The status of diabetes control in Asia - a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998
LM Chuang et al.
DIABETIC MEDICINE (2002)
Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
SE Inzucchi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Mechanism by which metformin reduces glucose production in type 2 diabetes
RS Hundal et al.
DIABETES (2000)
分享论文
